ATE411056T1 - Lymphombehandlung mit dem monoklonalen anti- tenascin-antikörper - Google Patents

Lymphombehandlung mit dem monoklonalen anti- tenascin-antikörper

Info

Publication number
ATE411056T1
ATE411056T1 AT01996085T AT01996085T ATE411056T1 AT E411056 T1 ATE411056 T1 AT E411056T1 AT 01996085 T AT01996085 T AT 01996085T AT 01996085 T AT01996085 T AT 01996085T AT E411056 T1 ATE411056 T1 AT E411056T1
Authority
AT
Austria
Prior art keywords
antibody
monoclonal
antitenascin
antibodies
lymphoma
Prior art date
Application number
AT01996085T
Other languages
English (en)
Inventor
David Rizzieri
Darell Bigner
Michael Zalutsky
Original Assignee
Univ Duke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Duke filed Critical Univ Duke
Application granted granted Critical
Publication of ATE411056T1 publication Critical patent/ATE411056T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT01996085T 2000-12-21 2001-10-24 Lymphombehandlung mit dem monoklonalen anti- tenascin-antikörper ATE411056T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25710800P 2000-12-21 2000-12-21

Publications (1)

Publication Number Publication Date
ATE411056T1 true ATE411056T1 (de) 2008-10-15

Family

ID=22974925

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01996085T ATE411056T1 (de) 2000-12-21 2001-10-24 Lymphombehandlung mit dem monoklonalen anti- tenascin-antikörper

Country Status (6)

Country Link
US (2) US20020187100A1 (de)
EP (1) EP1351713B1 (de)
AT (1) ATE411056T1 (de)
DE (1) DE60136221D1 (de)
ES (1) ES2314002T3 (de)
WO (1) WO2002051448A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060127311A1 (en) * 2004-11-17 2006-06-15 Duke University Radiation dosimetry and blocking antibodies and methods and uses therefor in the treatment of cancer
US20060115862A1 (en) * 2004-11-17 2006-06-01 Duke University Anti-tenascin monoclonal antibody immunoassays and diagnostic kits
US20060257317A1 (en) * 2005-05-04 2006-11-16 Duke University Combination therapy in the treatment of cancer
SI2209805T1 (sl) 2007-10-30 2017-11-30 Philogen S.P.A. Antigen, povezan z revmatoidnim artritisom
WO2010090272A1 (ja) * 2009-02-06 2010-08-12 学校法人東京理科大学 慢性炎症治療剤及びこれに用いる抗体
CA2769882C (en) 2009-08-05 2016-10-11 Philogen S.P.A. Targeting of bone marrow neovasculature
CN111329994A (zh) 2012-10-03 2020-06-26 菲罗根股份公司 与炎性肠病有关的抗原

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
USRE38008E1 (en) * 1986-10-09 2003-02-25 Neorx Corporation Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
AU8547291A (en) * 1990-09-05 1992-03-30 Wistar Institute, The Monoclonal antibodies against tenascin
WO1994021293A1 (en) * 1993-03-19 1994-09-29 Duke University Method of treatment of tumors with an antibody binding to tenascin

Also Published As

Publication number Publication date
EP1351713A1 (de) 2003-10-15
US20020187100A1 (en) 2002-12-12
US20110217231A1 (en) 2011-09-08
WO2002051448A1 (en) 2002-07-04
DE60136221D1 (de) 2008-11-27
ES2314002T3 (es) 2009-03-16
EP1351713B1 (de) 2008-10-15
EP1351713A4 (de) 2005-09-07

Similar Documents

Publication Publication Date Title
ATE267610T1 (de) Glykosylierte igg antikörper
CL2010000791A1 (es) Anticuerpo monoclonales que se unen a integrina alfavbeta6 (7.7g5), composicion; hibridoma que lo produce (atcc pta-3899); usos para preparar un medicamento para tratar fibrosis, psoriasis, cancer y otros. (divisional solicitud n° 513-03)
AR007249A1 (es) Preparacion concentrada de anticuerpos
BR0012195A (pt) Método para tratar câncer de próstata num ser humano, artigo de fabricação e uso de um anticorpo que liga erbb2
WO1997046589A3 (en) Humanized antibodies that bind to the same antigen as bound by antibody nr-lu-13, and their use in pretargeting methods
DE60142342D1 (de) Antikörper gegen doppelintegrinen, zusammensetzungen, verfahren und verwendungen
ATE248605T1 (de) Für e-selectin und p-selectin spezifische kreuzreaktive monoklonale antikörper
AU9399501A (en) Therapeutic antibodies
NZ797493A (en) Anti-fgfr2 antibodies and methods of use thereof
BR0012196A (pt) Método de tratamento de um tumor em mamìferos através do uso de conjugados de maitansinóide e anticorpo receptor anti-erbb e artigo industrializado
AR050642A1 (es) Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/ calicheamicina
NZ337413A (en) Antibodies that bind to Prostate Stem Cell Antigen (PSCA) to treat prostate cancer.
ES2106195T3 (es) Anticuerpo igg aglicosilado anti cd3.
WO2003072036A3 (en) Treatment methods using anti-cd22 antibodies
GB2383331A (en) Monoclonal antibody DS6 Tumor-associated antigen CA6 and methods of use thereof
ATE364396T1 (de) Behandlung von pilzinfektion mit polyenen oder beta glucan synthese hemmern kombiniert mit anti- hsp antikörpern
WO2000074729A3 (en) Alpha or beta emitters to fragments in radioimmunotherapy
ATE411056T1 (de) Lymphombehandlung mit dem monoklonalen anti- tenascin-antikörper
EP1411962A4 (de) Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper
EA200400930A1 (ru) Блокирующее моноклональное антитело к vla-1 или его применение для лечения воспалительных заболеваний
DK1684770T3 (da) Oligo-beta-(1, 3) -glucan og monoklonale antistoffer mod kræft
WO2004050849A8 (en) Recombinant immunotoxin and use in treating tumors
ATE449856T1 (de) Humanisierte monoklonale antikörper die schützen gegen shigatoxininduzierte krankheiten
WO2004000216A3 (en) Anti-tenascin antibody fragments and minibodies for treatment of lymphoma
MX2024007035A (es) Anticuerpos anti-cdh6 y conjugados anticuerpo-farmaco de los mismos.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties